C
Circe Biosciences
Developing a manufacturing platform capable of producing any organic molecule using carbon dioxide, water, and electricity
About Circe Biosciences
Circe Biosciences, Inc. operates at the intersection of synthetic biology and decarbonization, developing a manufacturing platform that transforms carbon dioxide into a variety of valuable chemicals. The company was co-founded by Shannon Nangle and Marika Ziesack, who both bring extensive experience from the Wyss Institute for Biologically Inspired Engineering at Harvard University. Their collective background in gas fermentation and synthetic biology underpins the company's core technology. The process leverages gas fermentation, utilizing microbes that consume greenhouse gases like carbon dioxide, along with water and electricity, to produce a range of organic molecules.
The primary goal is to provide a sustainable alternative to traditional petrochemical-based manufacturing, thereby reducing the carbon footprint of numerous industries. Circe Biosciences' platform is designed to create products such as triglycerides for food production, bioplastics, and other specialty chemicals. This approach targets industries reliant on these materials, offering them a method to decarbonize their supply chains. The business model appears to be centered on producing and selling these sustainably sourced molecules or potentially licensing the technology to large-scale manufacturing partners. By converting a waste product (CO2) into essential goods, the company aims to build a more resilient and circular economy.
The company's platform functions by engineering microbes to be highly efficient at converting CO2 into specific target molecules. This fermentation process is positioned as a direct competitor to conventional methods that rely on fossil fuels. Significant milestones include securing a $1 million investment from The Engine, a venture firm with roots at MIT, which has provided crucial early-stage support. The company has also been recognized through various awards, including participation in the 2022 cohort of the Third Derivative accelerator program, underscoring its potential impact on climate technology. This technology offers the benefit of producing familiar products through a fundamentally different and more environmentally friendly pathway.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Boston, United States
- Employees
- 51
- Open positions
- None listed
- Dealroom signal
- 61.6/100
- Sub-industry
- Clean Energy, Innovative Food
- Sector
- Energy, Biotechnology, Spinout, Sustainable Development Goals, Fermentation, Biotechnology in Food, Climate Tech, Alternative Fats and Oils, DT and LS
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Sep 2024 | $5M | $40M | Bee Partners · Ponderosa Ventures · ReGen Ventures · Safar Partners | — |
| EARLY VC✓Equity / VC | May 2024 | $8M | $32M | Bee Partners · Undeterred Capital · ReGen Ventures · Elementum Ventures | ↗ |
Growth signals
Latest recorded traffic for Circe Biosciences is 410 monthly website visits, down 48.1% over the last three months. Circe Biosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
ARPA-E
Safar Partners
Exceptional Ventures
Climate Capital
Series A5 investors entered at this stage
Bee Partners
Undeterred Capital
ReGen Ventures
Elementum Ventures
Ponderosa Ventures
Other known investors4 additional known investors
Activate
Harvard University
Wyss Institute
Juniper
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Circe Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Circe Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







